33 results about "Trypanosoma" patented technology

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

The use of alkyl quaternary ammonium compounds including certain choline analogs for treating or preventing fungal and trypanosomal (e.g., Leishmaniasis) infections is described. These compounds, characterized as mono- and bis-alkyl ammonium compounds, were demonstrated to be highly effective in inhibiting growth of Candida albicans, Saccharomyces cerevisiae and Leishmania major. Quaternary ammonium compounds were previously known as effective antimalarial compounds in vivo but not recognized as antifungals or as anti-trypanosomals (e.g., anti-Leishmanials).

Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.

It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.

A compound represented by formula (I):

[wherein, for example, X is a hydrogen atom or a halogen atom;

R¹ is a hydrogen atom;

R² is a hydrogen atom or a C_1-4 alkyl group;

R³ is —CHO or —COOH; and

R⁴ is —CH═CH—(CH₂)_p—CH₃ (wherein p is an integer of 1 to 12), —CH(OH)—(CH₂)_q—CH₃ (wherein q is an integer of 1 to 13), —CH(OH)—CH₂—CH(CH₃)—(CH₂)₂—CH═C(CH₃)₂, —CH═CH—CH(CH₃)—(CH₂)₃—CH(CH₃)₂, —(CH₂)₂—CH(CH₃)—(CH₂)₃—CH(CH₃)₂ or —(CH₂)₈—CH₃], an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have antitrypanosoma activity, and accordingly are useful as drugs for preventing or treating the diseases caused by trypanosoma.

Methods for delivering potentially therapeutic or prophylactic protein and peptide agents to mammalian cells are provided. The agents are delivered by mutant trypanosomatid protozoa that have been genetically manipulated to code for such protein or peptide agents. The mutant protozoa additionally lack certain enzymes within the heme biosynthetic pathway, making the mutants susceptible to porphyria and eventual lysis.

The present invention provides novel enzymes, tryparedoxins, their isolation from Crithidia fasciculata, a method for the production thereof in genetically transformed bacteria, and their use as molecular targets for the discovery of trypanocidal drugs

The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.

The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein R^a, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections. The present invention further relates active ingredients, more specifically as medicaments for the treatment of kinetoplastid infections and pathologic conditions such as, but not limited to Trypanosomiasis, such as African trypanosomiasis, sleeping sickness, Chagas disease and leishmaniasis.

The invention relates to a new use of diphenyleneiodonium (DPI) as an active substance against parasites of the family Trypanosomatidae, in particular against parasites of the genus Leishmania and Trypanosoma.

The present invention provides the application of 17-ketosteroids and their derivatives, metabolites and precursors and pharmaceutically acceptable salts of these compounds in the treatment of malaria, African trypanosomiasis and American trypanosomiasis, or in alleviating or alleviating a certain For the application of one or more symptoms associated with malaria parasite or trypanosome infection, the above-mentioned compounds are collectively referred to as "compounds of the present invention". The present invention further relates to the use of said compounds in the treatment or prevention of one or more parasites and/or one or more diseases caused by said parasites, against one or more mycoplasma and/or one or more A disease caused by said mycoplasma, and/or against one or more of the following indications or infections and all other indications and infections: (a) hairy leukoplakia, (b) oral candidiasis, (c) Mouth ulcers - aphthous/herpetic/bacterial, (d) fungal candida, (e) human papillomavirus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) ) Kaposi's sarcoma oral lesions, (i) periodontitis, (j) necrotizing gingivitis, (k) orofacial herpes zoster, and (l) rotavirus. The compounds of the invention may also be used to alleviate or lessen one or more symptoms associated with the infections or diseases described herein.

The invention discloses a primer pair and kit for detecting a mouse trypanosome. By comparing a macrocyclic sequence of the mouse trypanosome with macrocyclic sequences of other similar trypanosomes, one primer pair TM2-F and TM2-R which can specifically detect the mouse trypanosome is screened, and sequences of the primer pair are shown in SEQ ID NO:1 and SEQ ID NO:2; the primer pair can specifically amplify a partial segment of the mouse trypanosome, is high in sensitivity and can detect a sample which contains 10 trypanosomes only or 1 ng DNA sample; and by utilizing the primer pair, the mouse trypanosome can be rapidly and accurately identified from other trypanozoons and leishmania amazonesis without an expensive microscope and professional etiology knowledge, detection is quick and convenient, and the primer pair can be used for detecting early infection, is also applicable to detection of animal trypanosome mixed infection, is beneficial to development of epidemiological investigation and can be applicable to detection of human mouse trypanosome infection.

The invention relates to a moringa oleifera leaf extract for treating trypanosoma brucei of pigs. The extract is used as a natural drug with effective ingredients of flavonoids, tannins, saponins, steroids, phenols carbohydrates and glycosides according to chemical analysis. The pigs infected with the trypanosoma bruce have weight loss and die within 15 days of infection. At present, chemical methods are mainly adopted for treatment and prevention in the market, but there is a common problem that chemical drugs have drug resistance. With a view to screening of natural anti-parasitic drugs, moringa oleifera leaves are selected and crushed to obtain the moringa oleifera leaf extract to treat the trypanosoma brucei. Experiments show that degeneration of brain neuron cells caused by the trypanosoma brucei can be effectively controlled 14days after acute dosing before infection with the trypanosoma brucei. The extract contributes to weight gain of the pigs. Therefore, the natural drug is agood lead drug for anti-parasitic diseases. On this basis, the trypanosoma brucei can be well treated by further separation of the active ingredients.